Back

Mitochondrial ATP production promotes T cell differentiation and function by regulating chromatin accessibility

Ng, C.; Fung, T. S.; Li, D.; Kropp, K. N.; Somarribas Patterson, L. F.; Markovitz, A.; Weinberg, D. N.; Jones, O.; Kim, J.-Y.; Zhang, G.; Koche, R.; Monetti, M.; Tang, H.; He, Y.; Xu, Z.; Cai, X.; Yu, Z.; Bhagavatula, G.; Colgan, S. P.; Lin, Y.-H.; Li, Z.; Steinert, E. M.; Klebanoff, C. A.; Vardhana, S. A.; Chandel, N. S.; Wu, L.; Thompson, C. B.

2026-03-28 immunology
10.64898/2026.03.27.714789 bioRxiv
Show abstract

Immune elimination of chronic infection or cancer requires cytotoxic CD8+ T cells that adopt and maintain an effector phenotype. Cytotoxic T cell function is a bioenergetically demanding process and T cells subjected to chronic antigen exposure have compromised effector function despite high rates of glycolysis. Here we report the ability of the short-chain -hydroxy acid, D--hydroxybutyrate, to act as a signaling molecule that increases mitochondrial ATP production and drives the conversion of proliferating T cells into cytotoxic effector cells. DAHB signaling switches ATP production from glycolysis to oxidative phosphorylation supported by fatty acid oxidation, even in glucose-replete media. This conversion suppresses both AMPK phosphorylation and the integrated stress response (ISR) in activated T cells while significantly elevating the level of the phosphagen, phosphocreatine (PCr). Both the PCr bioenergetic reserve and oxidative phosphorylation were required for T cell effector differentiation. DAHB-induction of CD8-effector gene transcription was coupled to bioenergetics by enhanced ATP-dependent remodeling of chromatin accessibility at effector gene loci. DAHB enhanced CD8+ T cell antitumor activity both in vitro and in vivo, and DAHB treatment of transferred T cells led to persistent in vivo antitumor effects. Together, these findings link cellular bioenergetics to the regulation of chromatin accessibility and gene expression required to support effector function.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cell Reports
1338 papers in training set
Top 2%
12.0%
2
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 6%
9.8%
3
Cell Metabolism
49 papers in training set
Top 0.1%
9.8%
4
Nature Communications
4913 papers in training set
Top 24%
8.0%
5
eLife
5422 papers in training set
Top 12%
6.6%
6
Nature Metabolism
56 papers in training set
Top 0.3%
6.2%
50% of probability mass above
7
Nature Immunology
71 papers in training set
Top 0.5%
3.8%
8
Science
429 papers in training set
Top 9%
3.5%
9
EMBO reports
136 papers in training set
Top 1%
3.5%
10
Immunity
58 papers in training set
Top 2%
3.5%
11
Journal of Cell Biology
333 papers in training set
Top 1%
2.5%
12
Journal of Experimental Medicine
106 papers in training set
Top 2%
2.0%
13
Science Advances
1098 papers in training set
Top 14%
2.0%
14
Science Immunology
81 papers in training set
Top 1%
1.8%
15
Molecular Cell
308 papers in training set
Top 7%
1.6%
16
Science Signaling
55 papers in training set
Top 0.1%
1.6%
17
Cell
370 papers in training set
Top 12%
1.6%
18
PLOS Biology
408 papers in training set
Top 11%
1.6%
19
Nucleic Acids Research
1128 papers in training set
Top 14%
1.2%
20
EMBO Reports
88 papers in training set
Top 0.4%
0.9%
21
mBio
750 papers in training set
Top 11%
0.8%
22
Cell Chemical Biology
81 papers in training set
Top 3%
0.8%
23
Cell Systems
167 papers in training set
Top 11%
0.8%
24
Cancer Discovery
61 papers in training set
Top 2%
0.7%
25
Cell Reports Medicine
140 papers in training set
Top 8%
0.7%
26
Nature
575 papers in training set
Top 16%
0.7%
27
The EMBO Journal
267 papers in training set
Top 6%
0.7%
28
PLOS Pathogens
721 papers in training set
Top 9%
0.7%
29
iScience
1063 papers in training set
Top 39%
0.6%
30
Gastroenterology
40 papers in training set
Top 2%
0.6%